Limited information is available in the medical literature on epidemic Kapo
si sarcoma (EKS) of the foot. Patients with EKS of the foot can experience
severe discomfort that makes it difficult to ambulate and even wear shoes.
Between 1985 and 1996, 36 patients with EKS of the foot were treated with p
alliative intent. Most patients were referred for radiation therapy because
of foot discomfort or marked difficulty with ambulation. From the pool of
36 patients, data were available at completion of treatment for 46 sites, a
nd at 1 month for 44 sites. Morbidity was assessed for 35 sites. The median
follow-up time for the 44 sites with at least 1 month follow-up was 8 mont
hs. The most frequently used regimen was a novel Fractionation schedule of
three fractions a week at 3.5 Gy/fx to a total dose of 21.0 Gy. The overall
response rate and complete response rate for the 44 sites with at least 1
month follow-up were 91% and 80%, respectively. The 46 treated sites evalua
ted at the completion of treatment had a complete response rate of only 13%
and an overall response rate of 63%. Of the 35 sites assessed for acute to
xicity, 63% experienced discomfort related to the radiation therapy. This d
iscomfort usually resolved without intervention within 2 weeks of completio
n of radiation therapy. For patients with and without a history of opportun
istic infections, complete responses were observed in 8 of 12 sites (67%) a
nd 25 of 27 sites (93%), respectively (p = 0.06). Radiation therapy for EKS
of the foot yields excellent response rates, comparable with responses see
n in other cutaneous sites with EKS. Appropriate patient education and supp
ort are needed because initial responses to radiation therapy are often dis
appointing and pedal discomfort can be exacerbated transiently. However, th
e discomfort resolves and complete response occurs in most patients. The 3.
5-Gy triweekly fractionation schedule is a convenient and effective regimen
and minimizes treatment visits for patients with ambulatory discomfort. A
history of opportunistic infections appears to be a poor prognosticator of
response to radiation treatments.